Research programme: cancer therapeutics - ArQule/Beryllium

Drug Profile

Research programme: cancer therapeutics - ArQule/Beryllium

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule; Beryllium
  • Class Small molecules
  • Mechanism of Action CD274 antigen inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Nov 2016 ArQule and Beryllium jointly terminate the research and development agreement for programmed cell death protein and ligand inhibitors in Cancer (ArQule's form 10-K, filed in March 2017)
  • 04 Nov 2016 Discontinued for Cancer in USA, as the agreement between the companies was terminated (ArQule's form 10-K, filed in March 2017)
  • 20 May 2015 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top